Kirk Hartley

Latest from Kirk Hartley

The abstract pasted below was not an April fool’s joke. To the contrary, it illustrated the increasing efforts to combine in silico and in vitro analysis to predict in vivo outcomes, and to extrapolate across biologic systems. The abstract is online here, as of April 1, 2019, at Environmental Health Perspectives. “Abstract Background: Low-cost, high-throughput in vitro bioassays have potential as alternatives to animal models for toxicity testing. However, incorporating in vitro bioassays into chemical…
For persons facing cancer in the Chicago area, May 11, 2019 will bring a local opportunity to learn about the entire range of legal rights of persons during and after cancer. The location is a conference room at a hotel near O’Hare. Triage Cancer is a one of a kind national not for profit lead by two lawyers who are by far the national leaders on this topic. Indeed, Joanna Morales and Monica Bryant…
There’s never enough time to fully track asbestos developments in Europe. However, a December 2018 article from Clyde & Co, caught my eye and is worth reading as to the assessment of defense side lawyer regarding the evidence needed for a plaintiff to prevail on secondary exposure cases, and trial practice in Scotland. The conclusions were as follows: “What can we learn? These cases were heard within a period of a few weeks of each…
Yesterday brought the issuance of dozens of papers about the importance – or not – of p-values. That’s important news for trial lawyers, corporate officers, corporate directors, and risk managers. Persons in those roles (and others) are in for surprises if not aware of and ready for debates about and likely reduction in the litigation-related power of p values. Indeed, the many papers issued yesterday on use of statistics deserve attention when thinking about opportunities…